Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

A. G. Waks, O. Cohen, B. Kochupurakkal, D. Kim, C. E. Dunn, J. Buendia Buendia, S. Wander, K. Helvie, M. R. Lloyd, L. Marini, M. E. Hughes, S. S. Freeman, S. P. Ivy, J. Geradts, S. Isakoff, P. LoRusso, V. A. Adalsteinsson, S. M. Tolaney, U. Matulonis, I. E. KropA. D. D'Andrea, E. P. Winer, N. U. Lin, G. I. Shapiro, N. Wagle

Research output: Contribution to journalArticlepeer-review

127 Scopus citations

Fingerprint

Dive into the research topics of 'Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry